Abstract
Nearly 1/6th of the world population are affected with elevated blood pressure due to various etiology. Pharmacologically, hypertension can be controlled with a wide variety of pharmacotherapeutic compounds each falling into a distinct class of drugs. Multiple organs like brain, kidney, blood vessels and heart, various receptors and hormones tightly fine-tune the blood pressure in humans. Hence, drugs like ACEI, ARBs, CCBs, beta-blockers, alpha-blockers, and various others are employed to treat hypertension. Besides drug therapy, dietary and lifestyle modifications play an equal role in controlling hypertension. The choice of antihypertensive agents is specific for each patient and it depends upon the various type of factors like personality, age, race, occupation, comorbid conditions. This chapter will review the clinical pharmacology of antihypertensive drugs used commonly to control hypertension with additional focus on the choice of drug for specific conditions associated with the hypertensive emergency.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Bibliography
Amery A, Birkenhäger W, Bulpitt CJ, Clément D, De Leeuw P, Dollery CT et al (1991) Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging (Milano) 3(3):287–302
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), National Heart, Lung, and Blood Institute (NHLBI) (n.d.). https://www.nhlbi.nih.gov/science/antihypertensive-and-lipid-lowering-treatment-prevent-heart-attack-trial-allhat. Accessed 19 Sep 2019
Armstrong C (2014) JNC8 guidelines for the Management of Hypertension in adults. AFP 90(7):503–504
Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H et al (1997) The losartan intervention for endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 10(7 Pt 1):705–713
Gerstein HC (2001) Diabetes and the HOPE study: implications for macrovascular and microvascular disease. Int J Clin Pract Suppl 117:8–12
Ginsberg HN (2011) The ACCORD (action to control cardiovascular risk in diabetes) lipid trial: what we learn from subgroup analyses. Diabetes Care 34(Suppl 2):S107–S108
Meurin P (2006) The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension. Am J Cardiovasc Drugs 6(5):327–334
Ostergren J, Poulter NR, Sever PS, Dahlöf B, Wedel H, Beevers G et al (2008) The Anglo-Scandinavian cardiac outcomes trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens 26(11):2103–2111
Sleight P (2000) The HOPE study (heart outcomes prevention evaluation). J Renin-Angiotensin-Aldosterone Syst 1(1):18–20
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Lakshmanan, M. (2021). Antihypertensive Agents. In: Paul, A., Anandabaskar, N., Mathaiyan, J., Raj, G.M. (eds) Introduction to Basics of Pharmacology and Toxicology. Springer, Singapore. https://doi.org/10.1007/978-981-33-6009-9_24
Download citation
DOI: https://doi.org/10.1007/978-981-33-6009-9_24
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-33-6008-2
Online ISBN: 978-981-33-6009-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)